Tempest Therapeutics (TPST) Accumulated Expenses (2011 - 2026)
Tempest Therapeutics (TPST) posted Accumulated Expenses of $147000.0 for Q4 2025, down 89.14% sequentially from $1.4 million in Q3 2025, and up 149.15% YoY from $59000.0 in Q4 2024.
Tempest Therapeutics (TPST) Accumulated Expenses (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Accumulated Expenses for 15 years, with the latest figure at $147000.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 149.15% year-over-year to $147000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $147000.0 (up 149.15% YoY) and the FY2025 annual result came in at $147000.0, up 149.15% from the prior year.
- Accumulated Expenses retreated to $147000.0 in Q4 2025 per TPST's latest filing, from $1.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.6 million in Q3 2022 and troughed at $59000.0 in Q4 2024.
- A 5-year average of $838050.0 and a median of $557000.0 in 2021 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2024: Accumulated Expenses slumped 98.63% in 2021, then surged 1222.64% in 2024.
- Over 5 years, Accumulated Expenses stood at $1.6 million in 2021, then slipped by 21.46% to $1.2 million in 2022, then tumbled by 90.95% to $113000.0 in 2023, then plunged by 47.79% to $59000.0 in 2024, then jumped by 149.15% to $147000.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $147000.0, $1.4 million, and $101000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 715,000.00 |
| Dec 31, 2025 | 147,000.00 |
| Sep 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 101,000.00 |
| Mar 31, 2025 | 718,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 106,000.00 |
| Mar 31, 2024 | 110,000.00 |
| Dec 31, 2023 | 113,000.00 |
| Sep 30, 2023 | 106,000.00 |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2023 | 450,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 2.59 Mn |
| Jun 30, 2022 | 2.19 Mn |
| Mar 31, 2022 | 330,000.00 |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 664,000.00 |
| Jun 30, 2021 | 948,000.00 |